Novo Hit With Another Monopoly Suit Over Prandin
Novo Nordisk A/S has once again been hit with accusations that it manipulates the U.S. Food and Drug Administration's generics approval process as part of an alleged scheme to stunt competition...To view the full article, register now.
Already a subscriber? Click here to view full article